CEO John Oyler Files to Sell $45.4M in BeOne Medicines Stock Under 10b5-1 Plan
ONC sits 20% above its 52-week low of $249.
Summary
BeOne Medicines CEO John V. Oyler filed to sell 150,000 ADSs (~$45.4M) under a 10b5-1 plan adopted in March 2026, adding to a recent pattern of insider selling.
Key Events · Ownership and Investor Activity · ONC
-
CEO Files to Sell $45.4M in Stock
John V. Oyler, CEO and Director, filed a Form 144 to sell 150,000 ADSs with an approximate market value of $45,424,500. The sale is scheduled for on or about July 10, 2026.
-
Sale Under Pre-Existing 10b5-1 Plan
The planned sale is pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026, indicating the transaction was pre-scheduled and not based on current material non-public information.
-
Shares Acquired via Option Exercise
The 150,000 ADSs to be sold were acquired on July 10, 2026 through the exercise of stock options, with cash payment to the issuer.
-
Recent Insider Selling Pattern
Over the past 90 days, eight insiders have sold a net $2.68 million in open-market transactions, and Oyler himself sold 13,992 shares for $3.75 million in the prior three months.
Analysis · ONC · Life Sciences
CEO John V. Oyler has filed a Form 144 to sell 150,000 ADSs worth approximately $45.4 million. The sale is part of a pre-arranged 10b5-1 trading plan adopted on March 10, 2026, which reduces the signaling impact but still represents a significant monetization event. This follows a pattern of insider selling—eight insiders have sold $2.68 million in the past 90 days—and comes amid a strong stock run fueled by FDA approval of BEQALZI and robust Q1 results. While the sale is planned and not necessarily a red flag on fundamentals, the size is notable and may pressure the stock near-term.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONC was trading at $298.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.9B. The 52-week trading range was $249.00 to $385.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.